The Company and Summary of Significant Accounting Policies (Details Narrative)	3 Months Ended			6 Months Ended			12 Months Ended
	Jun. 30, 2023 EUR (€) shares	Jun. 30, 2023 USD ($) shares	Jun. 30, 2022 shares	Jun. 30, 2023 EUR (€) shares	Jun. 30, 2023 USD ($) shares	Jun. 30, 2022 shares	Dec. 31, 2022 EUR (€) shares
Current liabilities exceeding current assets | €	€ 74,347			€ 74,347
Preferred stock shares authorized | shares	5,000,000			5,000,000			5,000,000
Potentially shares issuable | shares	820,925,100	820,925,100	784,480,472	820,925,100	820,925,100	784,480,472
Potentially shares issuable convertible loans | shares	795,175,100	795,175,100	758,730,472	795,175,100	795,175,100	758,730,472
Sub award grant revenue USD		$ 116			$ 404
Accumulated deficit | €	€ (112,101,000)			€ (112,101,000)			€ (102,555,000)
Sub award grant revenue euro | €	€ 106			€ 376
Basic weighted and diluted | shares	303,757,622	303,757,622	303,757,622	303,757,622	303,757,622	303,757,622
Budget description				The overall budget related to the project is US$8,850 with US$8,761 approved for the period of (May 2019 to April 2024). This includes the funds approved for the period of (May 2023 to April 2024) of US$1’630	The overall budget related to the project is US$8,850 with US$8,761 approved for the period of (May 2019 to April 2024). This includes the funds approved for the period of (May 2023 to April 2024) of US$1’630
Grant allocated description				The amounts mentioned in the following statements are purely related to the Company and not to the other partners in the project: The overall portion of the grant allocated to the Company is US$4,052 approved for the period of (May 2019 to April 2024). This includes the funds approved for the period of (May 2023 to April 2024) of US$97	The amounts mentioned in the following statements are purely related to the Company and not to the other partners in the project: The overall portion of the grant allocated to the Company is US$4,052 approved for the period of (May 2019 to April 2024). This includes the funds approved for the period of (May 2023 to April 2024) of US$97
Grant Revenue [Member]
Concentration risk percentage				99.00%	99.00%	99.00%	100.00%
First Year [Member]
Sub award grant revenue USD					$ 599
Sub award grant revenue euro | €				€ 542
Sub award project cost USD					743
Second Year [Member]
Sub award grant revenue USD					1,048
Sub award grant revenue euro | €				909
Sub award project cost USD					1,319
Third Year [Member]
Sub award grant revenue USD					986
Sub award grant revenue euro | €				899
Sub award project cost USD					1,078
Fourth Year [Member]
Sub award grant revenue USD					674
Sub award grant revenue euro | €				638
Sub award project cost USD					815
Five Year [Member]
Sub award grant revenue USD | €				19
Sub award grant revenue euro | €				17
Sub award project cost USD					97
Revanue form NIH [Member]
Sub award grant revenue USD					$ 3,326
Sub award grant revenue euro | €				€ 3,005
Stock Option [Member]
Potentially shares issuable | shares	25,750,000	25,750,000	25,750,000	25,750,000	25,750,000	25,750,000